L&G Pharma Breakthrough UCITS ETF | BIOT

Register to Unlock Ratings
Performance History30/09/2024
Growth of 1,000 (GBP) Advanced Graph
L&G Pharma Breakthrough UCITS ETF
          | 
          BIOT
Fund23.2-3.04.4-15.3-2.2
+/-Cat-2.86.112.3-14.0-0.9
+/-B’mrk-9.8-3.32.0-22.7-9.0
 
Key Stats
Closing Price
04/10/2024
 USD 10.66
Day Change 0.29%
Morningstar Category™ Sector Equity Biotechnology
Volume 3
Exchange LONDON STOCK EXCHANGE, THE
ISIN IE00BF0H7608
Fund Size (Mil)
04/10/2024
 USD 18.22
Share Class Size (Mil)
04/10/2024
 USD 18.22
Ongoing Charge
14/02/2024
  0.49%
Investment Objective: L&G Pharma Breakthrough UCITS ETF | BIOT
The investment objective of the Fund is to provide exposure to bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. In order to achieve this investment objective, the Fund will seek to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). It will do so by investing primarily in a portfolio of equity securities that, as far as possible and practicable, consists of the component securities of the Index in similar proportions to their weightings in the Index and may have exposure to or invest directly up to 20% of its Net Asset Value in shares issued by the same body, which limit may be raised to 35% for a single issuer in exceptional market conditions, including (but not limited to) circumstances in which such issuer occupies a dominant market position.
Returns
Trailing Returns (GBP)04/10/2024
YTD-1.00
3 Years Annualised-4.80
5 Years Annualised2.58
10 Years Annualised-
12 Month Yield 0.00
Management
Manager Name
Start Date
-
-
Inception Date
18/01/2018
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
Solactive Pharma Breakthrough V NR USDMorningstar Gbl Biotechnology NR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNo
GrowthYes
IncomeNo
HedgingNot Specific
OtherYes
Portfolio Profile for  L&G Pharma Breakthrough UCITS ETF | BIOT04/10/2024
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock99.920.0099.92
Bond0.000.000.00
Property0.000.000.00
Cash0.080.000.08
Other0.000.000.00
Top 5 Regions%
United States53.54
Japan15.50
Europe - ex Euro9.77
Asia - Emerging7.14
Eurozone5.86
Top 5 Sectors%
Healthcare96.97
Basic Materials3.03
Top 5 HoldingsSector%
InnoCare Pharma LtdHealthcareHealthcare3.63
BeiGene Ltd ADRHealthcareHealthcare3.50
Xeris Biopharma Holdings IncHealthcareHealthcare3.19
Pharma Mar SAHealthcareHealthcare3.06
LG Chem LtdBasic MaterialsBasic Materials3.03
L&G Pharma Breakthrough UCITS ETF | BIOT

Related

In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures